FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522433691> ?p ?o ?g. }

• W2522433691 endingPage "4268" @default.
• W2522433691 startingPage "4268" @default.
• W2522433691 abstract "Background The international prognostic index (IPI) was first described in 1993 by Shipp et al and is the most commonly used prognostication tool in DLBCL. The IPI combines 5 poor prognostic parameters (age >60 years, elevated LDH, performance status ≥2, stage III/IV and >1 site of extranodal disease). Use of the age-adjusted IPI (AA-IPI) is recommended for patients 1 extranodal site of disease was no longer prognostic. In this analysis, we explored the prognostic implications of individual IPI parameters including >1 site of extranodal disease in the context of a large randomized phase III study.Methods The R-CHOP 14 versus 21 phase 3 open-label randomised controlled trial has been previously reported [Cunningham et al, The Lancet, Volume 381, Issue 9880, p1817-1826]. 1080 patients were randomly assigned to receive six cycles of R-CHOP every 14 days plus 2 cycles of rituximab (R-CHOP-14) or eight cycles of R-CHOP every 21 days (R-CHOP-21).A multivariate analysis of prognostic factors was also undertaken, including age (continuous variable), gender, stage (I-IV), performance status (PS; 0 vs 1 vs 2), lactate dehydrogenase (LDH) concentration (normal vs elevated), presence or absence of B symptoms and number of extranodal sites ( 1). We particularly wished to assess whether >1 site of extranodal disease is an independent prognostic factor in our dataset, both in all treated patients (n=1071) and in those<60 years (n=473). A comparison of overall survival (OS) between the standard IPI and AA-IPI groupings was performed in patients<60 years using the Kaplan Meier (KM) method.Results In multivariate analysis increased age, stage, and PS, as well as raised LDH and presence of B symptoms were associated with poor OS. Whilst >1 site of extranodal disease was not found to be independently prognostic, it was associated with a non-significant trend towards poorer OS (HR 1.312, p=0.057). When the analysis was restricted to patients 1 extranodal site of disease was found to be associated with a significantly worse OS (HR 2.19, p=0.0025). This is in contrast to the original age-adjusted IPI which did not find >1 extranodal site to be a relevant prognostic factor in the<60 years group.[Table 1][1] displays the effects of >1 extranodal site on OS and PFS. OS in patients<60 years according to standard IPI and AA-IPI are shown in [figures 1][2] and [2][3]. Using the AA-IPI (which excludes weighting for number of extranodal sites) the poorest prognostic group have a 2 yr OS of 55%. Using the standard IPI in the same population there appears to be better differentiation of prognostic groups with the poorest prognostic group having a 2 yr OS of 40%.View this table:Table 1 Prognostic significance of >1 extranodal site of disease in multivariate analysis (OS and PFS)![Figure 1:][4] Figure 1: IPI score and overall survival in patients<60 years (n=476)![Figure 2:][4] Figure 2: Age-adjusted IPI score and overall survival in patients<60years (n=476)Conclusion In our cohort of over 1000 patients from a randomized prospective phase III trial >1 extranodal site of disease was found to be associated with a significantly worse OS in patients<60 years with DLBCL. The use of the standard IPI was superior to the age-adjusted IPI in prognostication for patients<60 years in our dataset. Extranodal disease should be identified as a priority at baseline using modalities such as PET, to assign patients to the correct prognostic group. Accurate identification of poor risk patients will help to improve our understanding of their disease biology and guide future therapeutic strategies.Disclosures: Cunningham: Novartis: Research Funding; Astra-Zeneca: Research Funding; Merck KGA: Research Funding; Celgene: Research Funding; Sanofi-Aventis: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Hawkes: Roche: Travel expenses Other. Jack: Roche: Research Funding; Genentech: Research Funding. Pocock: Roche: Membership on an entity’s Board of Directors or advisory committees, Travel expenses Other; Pfizer: Membership on an entity’s Board of Directors or advisory committees. Ardeshna: Roche: Honoraria, Research Funding. Radford: Roche: Consultancy; Bayer-Schering: Consultancy; Millenium Pharmaceuticals: Consultancy, Research Funding; Napp Pharmaceuticals: Consultancy; Novartis: Consultancy; GlaxoSmithKline: Consultancy. McMillan: Roche: Consultancy, Honoraria, Research Funding, Travel expenses Other. Davies: Roche: Consultancy, Travel expenses Other. Turner: Roche: Travel expenses Other. Johnson: Roche: Membership on an entity’s Board of Directors or advisory committees, Travel expenses Other. Linch: Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Chugai Pharma: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity’s Board of Directors or advisory committees; Hospira: Membership on an entity’s Board of Directors or advisory committees; Celgene: Honoraria. [1]: #T1 [2]: #F1 [3]: #F2 [4]: pending:yes" @default.
• W2522433691 created "2016-09-30" @default.
• W2522433691 creator A5005708709 @default.
• W2522433691 creator A5006324385 @default.
• W2522433691 creator A5007119947 @default.
• W2522433691 creator A5009133053 @default.
• W2522433691 creator A5020200414 @default.
• W2522433691 creator A5022624109 @default.
• W2522433691 creator A5024744790 @default.
• W2522433691 creator A5033024327 @default.
• W2522433691 creator A5046426435 @default.
• W2522433691 creator A5053161231 @default.
• W2522433691 creator A5059004773 @default.
• W2522433691 creator A5059145854 @default.
• W2522433691 creator A5062645802 @default.
• W2522433691 creator A5064184281 @default.
• W2522433691 creator A5067838760 @default.
• W2522433691 creator A5086800637 @default.
• W2522433691 creator A5088439082 @default.
• W2522433691 date "2013-11-15" @default.
• W2522433691 modified "2023-10-02" @default.
• W2522433691 title "Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial" @default.
• W2522433691 doi "https://doi.org/10.1182/blood.v122.21.4268.4268" @default.
• W2522433691 hasPublicationYear "2013" @default.
• W2522433691 type Work @default.
• W2522433691 sameAs 2522433691 @default.
• W2522433691 citedByCount "0" @default.
• W2522433691 crossrefType "journal-article" @default.
• W2522433691 hasAuthorship W2522433691A5005708709 @default.
• W2522433691 hasAuthorship W2522433691A5006324385 @default.
• W2522433691 hasAuthorship W2522433691A5007119947 @default.
• W2522433691 hasAuthorship W2522433691A5009133053 @default.
• W2522433691 hasAuthorship W2522433691A5020200414 @default.
• W2522433691 hasAuthorship W2522433691A5022624109 @default.
• W2522433691 hasAuthorship W2522433691A5024744790 @default.
• W2522433691 hasAuthorship W2522433691A5033024327 @default.
• W2522433691 hasAuthorship W2522433691A5046426435 @default.
• W2522433691 hasAuthorship W2522433691A5053161231 @default.
• W2522433691 hasAuthorship W2522433691A5059004773 @default.
• W2522433691 hasAuthorship W2522433691A5059145854 @default.
• W2522433691 hasAuthorship W2522433691A5062645802 @default.
• W2522433691 hasAuthorship W2522433691A5064184281 @default.
• W2522433691 hasAuthorship W2522433691A5067838760 @default.
• W2522433691 hasAuthorship W2522433691A5086800637 @default.
• W2522433691 hasAuthorship W2522433691A5088439082 @default.
• W2522433691 hasConcept C121608353 @default.
• W2522433691 hasConcept C126322002 @default.
• W2522433691 hasConcept C143998085 @default.
• W2522433691 hasConcept C146357865 @default.
• W2522433691 hasConcept C151730666 @default.
• W2522433691 hasConcept C2776907518 @default.
• W2522433691 hasConcept C2778476033 @default.
• W2522433691 hasConcept C2778559949 @default.
• W2522433691 hasConcept C2779338263 @default.
• W2522433691 hasConcept C2779343474 @default.
• W2522433691 hasConcept C2779725641 @default.
• W2522433691 hasConcept C2780653079 @default.
• W2522433691 hasConcept C38180746 @default.
• W2522433691 hasConcept C71924100 @default.
• W2522433691 hasConcept C86803240 @default.
• W2522433691 hasConcept C90924648 @default.
• W2522433691 hasConceptScore W2522433691C121608353 @default.
• W2522433691 hasConceptScore W2522433691C126322002 @default.
• W2522433691 hasConceptScore W2522433691C143998085 @default.
• W2522433691 hasConceptScore W2522433691C146357865 @default.
• W2522433691 hasConceptScore W2522433691C151730666 @default.
• W2522433691 hasConceptScore W2522433691C2776907518 @default.
• W2522433691 hasConceptScore W2522433691C2778476033 @default.
• W2522433691 hasConceptScore W2522433691C2778559949 @default.
• W2522433691 hasConceptScore W2522433691C2779338263 @default.
• W2522433691 hasConceptScore W2522433691C2779343474 @default.
• W2522433691 hasConceptScore W2522433691C2779725641 @default.
• W2522433691 hasConceptScore W2522433691C2780653079 @default.
• W2522433691 hasConceptScore W2522433691C38180746 @default.
• W2522433691 hasConceptScore W2522433691C71924100 @default.
• W2522433691 hasConceptScore W2522433691C86803240 @default.
• W2522433691 hasConceptScore W2522433691C90924648 @default.
• W2522433691 hasIssue "21" @default.
• W2522433691 hasLocation W25224336911 @default.
• W2522433691 hasOpenAccess W2522433691 @default.
• W2522433691 hasPrimaryLocation W25224336911 @default.
• W2522433691 hasRelatedWork W2511557731 @default.
• W2522433691 hasRelatedWork W2531521052 @default.
• W2522433691 hasRelatedWork W2543307778 @default.
• W2522433691 hasRelatedWork W2558382780 @default.
• W2522433691 hasRelatedWork W2587962597 @default.
• W2522433691 hasRelatedWork W2597201295 @default.
• W2522433691 hasRelatedWork W2782731341 @default.
• W2522433691 hasRelatedWork W2787353251 @default.
• W2522433691 hasRelatedWork W2908656034 @default.
• W2522433691 hasRelatedWork W2911974825 @default.
• W2522433691 hasRelatedWork W2918287965 @default.
• W2522433691 hasRelatedWork W2921063325 @default.
• W2522433691 hasRelatedWork W2921646410 @default.
• W2522433691 hasRelatedWork W2964584109 @default.
• W2522433691 hasRelatedWork W2984009929 @default.
• W2522433691 hasRelatedWork W2984352195 @default.
• W2522433691 hasRelatedWork W3094749562 @default.

• next